{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:23:54Z","timestamp":1789471434933,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05255-3","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:29:19Z","timestamp":1775546959000},"page":"12923-12933","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of low-dose versus high-dose intravenous cyclophosphamide in Lupus Nephritis: A systematic review and Meta-analysis"],"prefix":"10.1007","volume":"399","author":[{"given":"Iftikhar","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soban Ali","family":"Qasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaria","family":"Firdous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aizaz Anwar","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Dawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umama","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Safdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafila","family":"Zeeshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal Wazir","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8208-0689","authenticated-orcid":false,"given":"Kamil Ahmad","family":"Kamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"5255_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0141-9","volume":"23;6(1)","author":"HJ Anders","year":"2020","unstructured":"Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C (2020) Lupus nephritis. Nat Rev Dis Primers 23;6(1):7","journal-title":"Nat Rev Dis Primers"},{"key":"5255_CR2","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"1;20(5)","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sa J, Solomons N, Wofsy D (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 1;20(5):1103\u20131112","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"5255_CR3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00296-007-0478-3","volume":"28","author":"S Appenzeller","year":"2008","unstructured":"Appenzeller S, Blatyta PF, Costallat LT (2008) Ovarian failure in SLE patients using pulse cyclophosphamide: comparison of different regimes. Rheumatol Int 28(6):567\u2013571","journal-title":"Rheumatol Int"},{"key":"5255_CR4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJM198603063141004","volume":"6;314(10)","author":"IIIHA Austin","year":"1986","unstructured":"Austin IIIHA, Klippel JH, Balow JE, Le Riche NG, Steinberg AD, Plotz PH, Decker JL (1986) Therapy of lupus nephritis. N Engl J Med 6;314(10):614\u2013619","journal-title":"N Engl J Med"},{"issue":"5","key":"5255_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00393-018-0512-8","volume":"78","author":"SC Bae","year":"2019","unstructured":"Bae SC, Lee YH (2019) Comparative efficacy and safety of low-dose and high-dose cyclophosphamide as induction therapy for lupus nephritis: a network meta-analysis. Z Rheumatol 78(5):467\u2013473","journal-title":"Z Rheumatol"},{"issue":"5","key":"5255_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.7326\/0003-4819-119-5-199309010-00003","volume":"119","author":"DT Boumpas","year":"1993","unstructured":"Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119(5):366\u2013369","journal-title":"Ann Intern Med"},{"issue":"1","key":"5255_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12026-009-8149-y","volume":"47","author":"RA Brodsky","year":"2010","unstructured":"Brodsky RA (2010) High-dose cyclophosphamide for autoimmunity and alloimmunity. Immunol Res 47(1):179\u2013184","journal-title":"Immunol Res"},{"key":"5255_CR8","doi-asserted-by":"crossref","unstructured":"Chan TM, Tse KC, Tang CS, Mok MY, Li FK, Hong Kong Nephrology Study Group (2005) Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16(4):1076\u201384.","DOI":"10.1681\/ASN.2004080686"},{"issue":"3","key":"5255_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188","journal-title":"Control Clin Trials"},{"key":"5255_CR10","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1136\/annrheumdis-2022-222276","volume":"1;81(9)","author":"A Duarte-Garc\u00eda","year":"2022","unstructured":"Duarte-Garc\u00eda A, Hocaoglu M, Valenzuela-Almada M, Osei-Onomah SA, Dabit JY, Sanchez-Rodriguez A, Duong SQ, Giblon RE, Langenfeld HE, Alarc\u00f3n GS, Helmick CG (2022) Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades. Ann Rheum Dis 1;81(9):1260\u20131266","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"5255_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00393-023-01386-7","volume":"83","author":"MM Elaziz","year":"2024","unstructured":"Elaziz MM, Gamal SM, Fayed A, Abu-Zaid MH, Ghoniem SA, Teleb DA (2024) High-and low-dose cyclophosphamide in Egyptian lupus nephritis patients: a multicenter retrospective analysis. Z Rheumatol 83(Suppl 1):115\u2013123","journal-title":"Z Rheumatol"},{"issue":"1","key":"5255_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, D\u00f6rner T (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83(1):15\u201329","journal-title":"Ann Rheum Dis"},{"key":"5255_CR13","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"24;353(21)","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 24;353(21):2219\u20132228","journal-title":"N Engl J Med"},{"issue":"7414","key":"5255_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"4","key":"5255_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/art.42375","volume":"75","author":"M Hocao\u01e7lu","year":"2023","unstructured":"Hocao\u01e7lu M, Valenzuela\u2010Almada MO, Dabit JY, Osei\u2010Onomah SA, Chevet B, Giblon RE, Zand L, Fervenza FC, Helmick CG, Crowson CS, Duarte\u2010Garc\u00eda A (2023) Incidence, prevalence, and mortality of lupus nephritis: a population\u2010based study over four decades using the Lupus Midwest Network. Arthritis Rheumatol 75(4):567\u2013573","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"5255_CR16","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/art.10461","volume":"46","author":"FA Houssiau","year":"2002","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D, Sebastiani GD, Garrido ED, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M (2002) Immunosuppressive therapy in lupus nephritis: the euro\u2010lupus nephritis trial, a randomized trial of low\u2010dose versus high\u2010dose intravenous cyclophosphamide. Arthritis Rheum 46(8):2121\u20132131","journal-title":"Arthritis Rheum"},{"key":"5255_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1046\/j.1523-1755.2000.00832.x","volume":"1;57(1)","author":"JP Ioannidis","year":"2000","unstructured":"Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, Moutsopoulos HM (2000) Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 1;57(1):258\u2013264","journal-title":"Kidney Int"},{"issue":"5","key":"5255_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2174\/1871530319666191107110420","volume":"20","author":"Y Li","year":"2020","unstructured":"Li Y, Xu S, Xu G (2020) Comparison of different uses of cyclophosphamide in lupus nephritis: a meta-analysis of randomized controlled trials. Endocr Metab Immune Disord Drug Targets 20(5):687\u2013702","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"4","key":"5255_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00296-018-3995-3","volume":"38","author":"S Mehra","year":"2018","unstructured":"Mehra S, Usdadiya JB, Jain VK, Misra DP, Negi VS (2018) Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study. Rheumatol Int 38(4):557\u2013568","journal-title":"Rheumatol Int"},{"issue":"5","key":"5255_CR20","first-page":"935","volume":"22","author":"AH Mitwalli","year":"2011","unstructured":"Mitwalli AH, Al Wakeel JS, Hurraib S, Aisha A, Al Suwaida A, Alam A et al (2011) Comparison of high and low dose of cyclophosphamide in lupus nephritis patients: a long-term randomized controlled trial. Saudi J Kidney Dis Transpl 22(5):935\u201340","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"5255_CR21","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ\u00a0372:n71.","DOI":"10.1136\/bmj.n71"},{"issue":"5","key":"5255_CR22","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/art.27371","volume":"62","author":"M Petri","year":"2010","unstructured":"Petri M, Brodsky RA, Jones RJ, Gladstone D, Fillius M, Magder LS (2010) High\u2010dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum 62(5):1487\u20131493","journal-title":"Arthritis Rheum"},{"key":"5255_CR23","doi-asserted-by":"publisher","unstructured":"Quevedo-Mayorga PA, Mora M\u00e9ndez JM, Aristiz\u00e1bal A, Estupi\u00f1\u00e1n Moya LM, Mu\u00f1oz D (2025) Systematic review and meta-analysis of the low-dose versus high-dose cyclophosphamide regimen for induction treatment in lupus nephritis patients: evidence update 2010\u20132023. Rev Colomb de Reumatol, [online] Available at: https:\/\/doi.org\/10.1016\/j.rcreue.2025.08.001","DOI":"10.1016\/j.rcreue.2025.08.001"},{"key":"5255_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ki.2015.318","volume":"1;89(1)","author":"M Rathi","year":"2016","unstructured":"Rathi M, Goyal A, Jaryal A, Sharma A, Gupta PK, Ramachandran R, Kumar V, Kohli HS, Sakhuja V, Jha V, Gupta KL (2016) Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int 1;89(1):235\u2013242","journal-title":"Kidney Int"},{"issue":"4","key":"5255_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DR (2021O) Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100(4):753\u2013779","journal-title":"Kidney Int"},{"issue":"3","key":"5255_CR26","first-page":"436","volume":"26","author":"SS Shabanova","year":"2008","unstructured":"Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II (2008) Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol 26(3):436\u2013441","journal-title":"Clin Exp Rheumatol"},{"key":"5255_CR27","doi-asserted-by":"crossref","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 366:14898.","DOI":"10.1136\/bmj.l4898"},{"issue":"51","key":"5255_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009408","volume":"96","author":"M Tian","year":"2017","unstructured":"Tian M, Song X, Dong L, Xin X, Dong J (2017) Systematic evaluation of different doses of cyclophosphamide induction therapy for lupus nephritis. Medicine 96(51):e9408","journal-title":"Medicine"},{"key":"5255_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/art.42725","volume":"76","author":"CS Wang","year":"2023","unstructured":"Wang CS, Sadun RE, Zhou W, Miller KR, Pyle L, Ardoin SP, Bacha C, Hause E, Hui-Yuen J, Ling N, Pereira M (2023) Renal response outcomes of the EuroLupus and NIH cyclophosphamide dosing regimens in childhood-onset proliferative lupus nephritis. Arthritis Rheumatol (Hoboken, NJ) 76:469\u2013478","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"1","key":"5255_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4103\/ijn.ijn_73_22","volume":"33","author":"DR Wijayaratne","year":"2023","unstructured":"Wijayaratne DR, Atukorala IG, Gunawardena NS, Wijesundara DA, Lanerolle RD (2023) Low-versus high-dose cyclophosphamide in class III\/IV lupus nephritis: a retrospective study from South Asia. Indian J Nephrol 33(1):40\u201345","journal-title":"Indian Journal of Nephrology"},{"issue":"1","key":"5255_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13048-025-01759-3","volume":"18","author":"J Wu","year":"2025","unstructured":"Wu J, Wei Y, Peng Q, Zhu J, Shi H, Zhao T, Yuan T (2025) Mechanisms of cell senescence and apoptosis in cyclophosphamide-induced premature ovarian failure in rats. J Ovarian Res 18(1):172","journal-title":"Journal of Ovarian Research"},{"issue":"5","key":"5255_CR32","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/ard.2002.003574","volume":"63","author":"CS Yee","year":"2004","unstructured":"Yee CS, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B, Rozman B, Isenberg DA, Sturfelt G, Nived O, Turney JH (2004) EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 63(5):525\u2013529","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"5255_CR33","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10067-014-2590-6","volume":"33","author":"XW Zhang","year":"2014","unstructured":"Zhang XW, Li C, Ma XX, Zhao JX, An Y, Liu S, Li Y, Li ZG (2014) Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study. Clin Rheumatol 33(7):939\u2013945","journal-title":"Clin Rheumatol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05255-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05255-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05255-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:44:52Z","timestamp":1783907092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05255-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5255"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05255-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review and meta-analysis of previously published studies, and no new human or animal subjects were involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}